SCM
Stonepine Capital Management Portfolio holdings
AUM
$102M
This Quarter Return
-10.11%
1 Year Return
+40.04%
3 Year Return
+160.28%
5 Year Return
+195.28%
10 Year Return
–
AUM
$301M
AUM Growth
+$301M
(+8.6%)
Cap. Flow
+$56M
Cap. Flow
% of AUM
18.61%
Top 10 Holdings %
Top 10 Hldgs %
83.86%
Holding
26
New
5
Increased
13
Reduced
3
Closed
3
Top Buys
| 1 |
Amylyx Pharmaceuticals
AMLX
|
$25.5M |
| 2 |
ALIM
Alimera Sciences, Inc.
ALIM
|
$12.3M |
| 3 |
GMDA
Gamida Cell Ltd. Ordinary Shares
GMDA
|
$6.66M |
| 4 |
Evolus
EOLS
|
$6.15M |
| 5 |
Galapagos
GLPG
|
$4.14M |
Top Sells
| 1 |
THRD
Third Harmonic Bio
THRD
|
$13.4M |
| 2 |
UroGen Pharma
URGN
|
$4.64M |
| 3 |
Castle Biosciences
CSTL
|
$1.26M |
| 4 |
MaxCyte
MXCT
|
$640K |
| 5 |
SCYNEXIS
SCYX
|
$214K |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
QuidelOrtho
QDEL
$1.95B
| $48.1M | 15.98% | 658,794 +39,368 | +6% | +$2.88M |
|
|
2
Evolus
EOLS
$494M
| $47.3M | 15.72% | 5,179,004 +672,807 | +15% | +$6.15M |
|
|
3
Amylyx Pharmaceuticals
AMLX
$836M
| $46.1M | 15.3% | 2,515,868 +1,394,840 | +124% | +$25.5M |
|
4
ADMA Biologics
ADMA
$4.12B
| $32.6M | 10.83% | 9,104,275 +310,954 | +4% | +$1.11M |
|
|
5
Galapagos
GLPG
$2.07B
| $27.7M | 9.21% | 802,544 +119,880 | +18% | +$4.14M |
|
|
ALIM
6
DELISTED
Alimera Sciences, Inc.
ALIM
| $12.3M | 4.1% | +3,983,686 | New | +$12.3M |
|
|
7
MaxCyte
MXCT
$148M
| $11.7M | 3.9% | 3,761,640 -205,276 | -5% | -$640K |
|
8
Xeris Biopharma Holdings
XERS
$1.26B
| $11M | 3.66% | 5,915,372 +415,144 | +8% | +$772K |
|
|
GMDA
9
DELISTED
Gamida Cell Ltd. Ordinary Shares
GMDA
| $8.2M | 2.73% | 7,965,865 +6,465,865 | +431% | +$6.66M |
|
|
ATYR
10
aTyr Pharma
ATYR
$527M
| $7.31M | 2.43% | 4,626,624 -600 | -0% | -$948 |
|
|
11
SCYNEXIS
SCYX
$34.9M
| $6.5M | 2.16% | 2,852,599 -93,747 | -3% | -$214K |
|
12
Xoma
XOMA
$392M
| $6.15M | 2.04% | 436,602 +87,203 | +25% | +$1.23M |
|
13
X4 Pharmaceuticals
XFOR
$84.2M
| $5.75M | 1.91% | 5,273,685 +668,422 | +15% | +$729K |
|
14
Atea Pharmaceuticals
AVIR
$267M
| $5.16M | 1.71% | 1,720,000 +967,912 | +129% | +$2.9M |
|
15
Rezolute
RZLT
$619M
| $4.06M | 1.35% | 3,072,476 | – | – |
|
16
TELA Bio
TELA
$70.5M
| $3.94M | 1.31% | 491,919 +9,300 | +2% | +$74.4K |
|
17
Exagen
XGN
$217M
| $2.91M | 0.97% | 1,203,491 +154,139 | +15% | +$373K |
|
18
IO Biotech
IOBT
$104M
| $2.79M | 0.93% | +1,975,308 | New | +$2.79M |
|
19
Gossamer Bio
GOSS
$562M
| $2.78M | 0.92% | +3,339,405 | New | +$2.78M |
|
20
Delcath Systems
DCTH
$385M
| $2.78M | 0.92% | 686,240 +307,453 | +81% | +$1.25M |
|
21
Assertio
ASRT
$80.4M
| $2.44M | 0.81% | +951,197 | New | +$2.44M |
|
22
Vanda Pharmaceuticals
VNDA
$279M
| $2.06M | 0.69% | +477,903 | New | +$2.06M |
|
23
AYTU BioPharma
AYTU
$21.1M
| $1.28M | 0.42% | 472,369 | – | – |
|
|
24
Castle Biosciences
CSTL
$696M
| – | – | -91,978 | Closed | -$1.26M |
|
|
THRD
25
DELISTED
Third Harmonic Bio
THRD
| – | – | -2,793,149 | Closed | -$13.4M |
|